Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2006
Reporting Period: Events occurring on May 1, 2006, and August 14, 2006.
The filing discloses the entry into material definitive agreements regarding the acquisition of proprietary technology for vascular access ports and a related license agreement necessary to commercialize said technology.
Key Financial Metrics and Agreements
This filing details specific contractual payment obligations rather than standard financial performance metrics (revenue, profit, cash flow). The filing text does not provide a clear value for the company's overall revenue, profit, margins, debt, or liquidity.
| Payment Obligation | Amount | Trigger/Date | Status |
|---|---|---|---|
| Initial Payment | $500,000 | May 1, 2006 | Completed |
| Second Payment | $1,500,000 | Execution of License Agreement or Sept 1, 2006 | Due (License executed Aug 14, 2006) |
| Third Payment | $3,500,000 | May 1, 2008 or First Commercial Sale | Future Contingent |
| Fourth Payment | $2,500,000 | Issuance of U.S. Patent (by May 1, 2016) | Future Contingent |
Total Potential Consideration: $8,000,000
Material Changes and Agreements
- Asset Purchase Agreement (May 1, 2006): AngioDynamics acquired all rights, title, and interest to proprietary technology relating to a vascular access port and a provisional patent application from Medron, Inc.
- License Agreement (August 14, 2006): To secure the ability to commercially exploit the acquired technology, the Company entered into a license agreement with a third party. This grants a nontransferable, exclusive, royalty-free, limited, worldwide license to a pending patent application.
- Reversion Clause: If the $1,500,000 second payment is not made by September 1, 2006, all rights to the Technology revert to the Seller (Medron, Inc.).
Outlook, Risks, and Contingencies
- Commercialization Requirement: The Company must use commercially reasonable efforts to commercialize licensed products within five years; failure to do so will terminate the License Agreement or render it nonexclusive.
- Patent Dependency: The value of the Purchase Agreement is potentially dependent on obtaining the third-party license, which was secured on August 14, 2006.
- Termination Risks: The License Agreement may be terminated for breach, bankruptcy, insolvency, or suspension of the Company's business.
- Reciprocal Licensing: The Company granted the third party a nonexclusive, irrevocable, royalty-free license to any know-how developed under the agreement for use in products other than vascular access ports.
Key Facts for Investor Verification
- Verify the execution of the $1,500,000 payment to Medron, Inc. prior to the September 1, 2006 deadline to prevent reversion of technology rights.
- Confirm the status of the third-party patent application licensed on August 14, 2006, and its potential impact on the exclusivity of the Company's vascular access port technology.
- Monitor the Company's progress toward commercializing the technology within the five-year window to maintain the exclusive license status.
- Assess the financial impact of the remaining $6,000,000 in contingent payments on future cash flow and balance sheet obligations.